Summary. Normal adult men and women have been infused with epinephrine, 6 /Ag per minute, during lipolytic blockade with nicotinic acid, beta-adrenergic blockade with propranolol and Butoxamine, and alpha-adrenergic blockade with phentolamine. Epinephrine infusion was associated with low serum levels of immunoreactive insulin (IRI) except when phentolamine was given simultaneously. These findings are compatible with an alpha receptor mechanism for the epinephrine inhibition of insulin release. Phentolamine had no blocking effects on the tachycardia and widened pulse pressure or lipolytic stimulation by epinephrine, whereas both propranolol and Butoxamine blocked lipolysis, tachycardia, and widened pulse pressure. These findings are consistent with an alpha receptor blocking action for phentolamine and beta receptor blocking action for propranolol and Butoxamine. Inhibition of lipolysis by nicotinic acid did not alter IRI or glucose responses to epinephrine.
Introduction
Infusions of epinephrine (1) and norepinephrine (2) recently have been shown to inhibit the release of serum immunoreactive insulin in man.
This inhibition of insulin release also has been demonstrated in pancreatic slices in vitro (3) , by pathologic study of the pancreas (4) , and by measurements of pancreatic venous blood insulin levels in animals in vivo (5) . Therefore, catecholamines presumably have a direct action on the secretion of insulin by pancreatic beta cells. Both the in vitro and in vivo effects are blocked by prior administration of dihydroergotamine (3, 4) , suggesting that adrenergic receptors similar to those responsible for the effects of catecholamines on muscle are involved. Two types of catecholamine receptor (alpha and beta) are presently believed to explain most of the results obtained in catechol stimulation studies, and a nomenclature proposed by Ahlquist (6) has been generally adopted to separate these receptors on a functional basis. The specific receptor responsible for the inhibiting effects of catecholamines upon insulin secretion RECEPTOR $ May cause tachycardia when given alone. § ,3 receptors may be present in some species. 1 1 Increased cycling of lactic acid to glucose in the liver may raise blood sugar. has not been elucidated because a) both epinephrine and norepinephrine stimulate both alpha and beta receptors, and b) ergotamine derivatives have been shown to block both alpha and beta receptor responses (7) (8) (9) (10) . During the past 5 years newer drugs that are more selective in their ability to block either alpha or beta receptors have been described (Table I) . These compounds have been used in the present study to define the receptor mechanism for the inhibition of insulin release by epinephrine.
MECHANISM FOR INHIBITION OF INSULIN RELEASE BY EPINEPHRINE

Methods
Subj ects selected were all ambulatory, apparently normal young adult men and women. A total of twenty studies were performed on nine men and six women. Volunteers were excluded if they exceeded their ideal body weight by more than 15% 1 or if there was a family history of diabetes mellitus. Some of the subjects were studied more than once. All subjects continued to eat their regular diet, but on the night before the study they were instructed to take no solid food after the evening meal and no liquids except water after midnight. No smoking was allowed on the day of the test. The volunteer subject on arrival at the Clinical Research Center was put to bed, and a slow intravenous drip of 0.85%o sodium NaCl was begun through each of two indwelling venous plastic catheters. Blood samples were withdrawn through one catheter and drugs and glucose infused through the other. No anticoagulants were given to the patient or were present in the sampling syringes. Blood rise in IRI levels. During the combined propranolol-epinephrine infusion all subjects were found to have mild hypertension and bradycardia rather than tachycardia and widened pulse pressure.
Butoxamine. Butoxamine was given to five subjects orally. The first subject received 3 mg Phentolamine. After a control period of 1 hour, five subjects were given a single rapid injection of 5 mg of phentolamine followed by a continuous infusion of phentolamine, 0.5 mg per minute, and epinephrine, 6 mg per minute for 1 hour. The glucose rise during these infusions was less than was found without phentolamine (1) or during nicotinic acid blockade. Free fatty acid stimulation of lipolysis was comparable to that found with epinephrine alone (1). IRI levels, however, were strikingly different .and were elevated in all subjects at all times during the infusions ( Figure 4 , Table V and also during a 4-hour epinephrine infusion ( Figure 5 ). None of the subjects given phentolamine alone showed any change in plasma glucose or serum IRI. In two there was a small and variable rise in FFA. All showed tachycardia and widened pulse pressure with phentolamine alone, and similar tachycardia and widened pulse pressure was found in all subjects given the combined phentolamine and epinephrine infusion. Although the combined phentolamine and epinephrine infusions had decreased the plasma glucose response to epinephrine somewhat, the one subject (R.R.) given phentolamine, both before and during epinephrine ( Figure 5 ), showed a much greater inhibition of glucose rise. In this subject, the maximal concentration of plasma glucose was 113 mg per 100 ml after 1 hour of epinephrine infusion, whereas it was 180 mg per 100 ml with nicotinic acid blockade and 166 mg per 100 ml with epinephrine alone (1). Discussion The concept that catecholamines produce effects by stimulating two types of receptors was originally proposed by Ahlquist (6) in studies involving skeletal, smooth, and cardiac muscle. His conclusions have been amply confirmed, but until recently there has been considerable confusion about the applicability of this concept to the known lipolytic and glycogenolytic stimulation by catecholamines. This confusion appears to have been resolved by more recent studies which show that both lipolysis in adipose tissue and glycogenolysis in liver and muscle can also be explained by a two receptor theory. Specifically, free fatty acid mobilization from adipose tissue and glycogenolysis in muscle appear to be beta-adrenergic effects (16) (17) (18) , whereas glycogenolysis in liver appears to be primarily a specific alpha-adrenergic receptor effect (18) , although beta receptor function has not been completely excluded in some species. The inhibition of insulin release by epinephrine was reversed only by simultaneous infusion of phentolamine. Most previous studies of this drug have been consistent with an alpha blockade action (19) . There was no inhibition of the lipolytic properties of epinephrine and no blockade of the usual tachycardia and widened pulse pressure. Although the latter observation is somewhat difficult to interpret, because phentolamine infusion alone will cause tachycardia and widened pulse pressure, both are consistent with an alpha receptor blockade, since free fatty acid mobilization, cardiac stimulation, and vasodilation are considered to be beta-stimulating effects of epinephrine (vida supra). The elevated IRI during phentolamine and epinephrine infusions was associated with significantly lower plasma glucose levels than were found during epinephrine infusions with nicotinic acid or propranolol, or during epinephrine infusion alone (1) . The lower glucose level presumably in part reflects the higher IRI response, but could be partly or entirely related to other effects of phentolamine upon epinephrinestimulated glycogenolysis in muscle or liver. The study does not allow an independent evaluation of these possibilities.
Propranolol, which has been reported to produce a specific beta-adrenergic blockade (20) , was associated during epinephrine infusions with IRI levels that fell significantly below basal, rather than remaining unchanged as found with epinephrine alone (1) or epinephrine and nicotinic acid. The present studies are completely compatible with a beta-adrenergic mechanism for propranolol blockade, since free fatty acid release was almost totally inhibited and tachycardia and widened pulse pressure were replaced by bradycardia and hypertension. Pretreatment with Butoxamine produced similar changes in both IRI and FFA, although the free fatty acid blockade was less complete. These effects were to be expected if the beta-adrenergic properties of epinephrine were blocked by both drugs, leaving the alpha-adrenergic-stimulating effects unhindered. The similar depression of basal insulin values (an exaggeration of the inhibiting effect of epinephrine) by these two drugs suggests either that stimulation of beta receptors releases insulin or that blockade of the beta-stimulating properties of catecholamines in some way enhances the IRI-inhibiting alpha-adrenergic effects. In other studies (21) isoproterenol, an apparently specific beta-stimulating catecholamine, has been found to stimulate insulin release in the absence of hyperglycemia. This observation would favor the latter hypothesis that beta stimulation by epinephrine results in stimulation of insulin release. Blockade of this beta stimulation would then be one possible ex-92 planation for the fall of IRI during epinephrine infusions with Butoxamine and propranolol. Intravenous propranolol had no acute effect on fasting free fatty acids, glucose, or IRI (five subjects at 5 minutes, two at 15 minutes), but oral Butoxamine reduced both free fatty acids and glucose in fasting subjects. The-mechanism for the fall in basal free fatty acid and glucose after Butoxamine is not clear from our study, but it is of interest that four of the five subjects showed small increases in IRI 30 and 60 minutes after the drug had been given. Although the magnitude of these IRI changes was quite variable, it seems possible that insulin release by Butoxamine might be related to an initial beta-adrenergic stimulation by the drug, causing effects similar to isoproterenol infusion (21) . Further studies seem necessary to evaluate this possibility.
Nicotinic acid has been shown to localize in adipose tissue and to block many hormonally induced stimuli to free fatty acid mobilization (22) . The present studies reaffirm this blocking effect in normal man. If the effect of epinephrine on insulin release were due to a specific adrenergic mechanism, one would not expect that blocking lipolysis would in any way change the response of IRI to epinephrine infusion. Since this was observed, it would appear that the lipolytic effect of epinephrine is totally unrelated to its inhibition of IRI release. The additional observation that lowering free fatty acids to 25% of their usual levels had no effect on fasting glucose or IRI, or on the IRI response to a small glucose challenge, is of particular interest. Randle, Garland, Hales, and Newsholme proposed from extensive in vitro studies that free fatty acid levels were important regulators of glucose entry into cells (23) . If this hypothesis were applicable to man, one would expect that marked changes in FFA in fasting subjects would be reflected by changes in either fasting glucose or IRI or both. One might also expect that the IRI or glucose response to a glucose load would be altered. The present observations do not confirm this hypothesis, since glucose and IRI concentrations were comparable to those observed previously without nicotinic acid blockade of FFA mobilization (1) . Further studies seem necessary, therefore, before the Randle hypothesis can be applied without modification to normal man.
